New tetanus antibody drug shows promise in early trial
NCT ID NCT05625477
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested an experimental drug called TNM002 in 240 healthy Chinese adults to see if it can protect against tetanus as well as the standard treatment. Participants received a single injection of TNM002 at different doses, the standard tetanus antibody, or a placebo. The main goal was to measure whether TNM002 raised tetanus-fighting antibodies to protective levels. The trial is now complete, and results will show if this new drug is a safe and effective alternative.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- TNM002 injection (an experimental antibody)
- What this could lead to
- If successful, TNM002 could offer a new option to prevent tetanus after injury, potentially with fewer side effects or easier production than current treatments.
- What could go wrong
- This is an early-phase trial with only 240 participants, so results may not apply to everyone. The experimental drug may not work as well as existing tetanus shots, and allergic reactions are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
240 people
The number who actually took part.
- Started
-
Apr 2022
- Finished
-
Oct 2022
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Chinese male or female adults aged ≥ 18 years; 2. Healthy volunteers or volunteers with stable chronic diseases; 3. Volunteers who provide signed written informed consent form. Exclusion Criteria: 1. History of allergy to the investigational product, human immunoglobulin preparation or any component of other therapeutic monoclonal immunoglobulins; 2. Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation; 3. History of alcohol or other substance abuse.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Tetanus are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
PKUCare Luzhong Hospital
Zibo, Shandong, China
-
The First Affiliated Hospital of Shantou University Medical College
Shantou, Guangdong, China
-
Wuxi People's Hospital
Wuxi, Jiangsu, China
-
Yunnan Provincial Hospital of Traditional Chinese Medicine
Kunming, Yunnan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tetanus immunity under the microscope: do antibodies hold up after 2.5 years?
- One shot, six protections: could a single vaccine replace multiple infant shots?
- Can one shot replace six? a new vaccine aims to protect infants from six diseases at once
- Can a Lab-Made antibody outperform standard tetanus shots?
- One shot, six protections: can a new vaccine match current standards?
- Can a new vaccine shield older kids and adults from three deadly infections?